Jessica Ravikoff Allegretti, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Clostridium Infections | 50 | 2023 | 548 | 13.970 |
Why?
|
Colitis, Ulcerative | 31 | 2024 | 1912 | 7.430 |
Why?
|
Inflammatory Bowel Diseases | 18 | 2023 | 2425 | 3.410 |
Why?
|
Crohn Disease | 15 | 2023 | 2303 | 3.200 |
Why?
|
Feces | 24 | 2023 | 1401 | 3.060 |
Why?
|
Pouchitis | 5 | 2023 | 62 | 2.750 |
Why?
|
Piperidines | 8 | 2024 | 1602 | 1.990 |
Why?
|
Colonic Pouches | 3 | 2023 | 121 | 1.720 |
Why?
|
Proctocolectomy, Restorative | 3 | 2023 | 189 | 1.650 |
Why?
|
Enterocolitis, Pseudomembranous | 4 | 2021 | 264 | 1.600 |
Why?
|
Bile Acids and Salts | 5 | 2023 | 367 | 1.490 |
Why?
|
Gastroenterology | 4 | 2024 | 536 | 1.450 |
Why?
|
Recurrence | 26 | 2023 | 8340 | 1.300 |
Why?
|
Gastrointestinal Agents | 5 | 2023 | 494 | 1.280 |
Why?
|
Remission Induction | 11 | 2023 | 2386 | 1.250 |
Why?
|
Pyrimidines | 8 | 2024 | 2942 | 1.220 |
Why?
|
Cholangitis, Sclerosing | 2 | 2019 | 159 | 1.210 |
Why?
|
Biological Products | 4 | 2024 | 860 | 1.150 |
Why?
|
Donor Selection | 7 | 2021 | 201 | 1.110 |
Why?
|
Anti-Bacterial Agents | 13 | 2023 | 7181 | 0.910 |
Why?
|
Treatment Outcome | 39 | 2023 | 63114 | 0.830 |
Why?
|
Immunologic Factors | 4 | 2021 | 1580 | 0.810 |
Why?
|
Preservation, Biological | 1 | 2020 | 25 | 0.750 |
Why?
|
Colonoscopy | 6 | 2020 | 1367 | 0.630 |
Why?
|
Humans | 111 | 2024 | 744343 | 0.630 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 820 | 0.570 |
Why?
|
Gastrointestinal Tract | 4 | 2024 | 814 | 0.530 |
Why?
|
Tissue Donors | 3 | 2019 | 2240 | 0.530 |
Why?
|
Treatment Failure | 6 | 2021 | 2618 | 0.500 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2023 | 4420 | 0.490 |
Why?
|
Stomach | 1 | 2018 | 697 | 0.480 |
Why?
|
Carrier State | 1 | 2017 | 518 | 0.470 |
Why?
|
Urinary Tract Infections | 1 | 2020 | 788 | 0.460 |
Why?
|
Antibiotic Prophylaxis | 1 | 2019 | 639 | 0.460 |
Why?
|
Retrospective Studies | 20 | 2024 | 77449 | 0.410 |
Why?
|
Anti-Inflammatory Agents | 2 | 2021 | 1790 | 0.410 |
Why?
|
Adult | 33 | 2024 | 214055 | 0.410 |
Why?
|
Intestine, Small | 1 | 2017 | 1241 | 0.390 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2015 | 387 | 0.390 |
Why?
|
Gastrointestinal Diseases | 1 | 2019 | 1170 | 0.380 |
Why?
|
Necrosis | 3 | 2024 | 1643 | 0.380 |
Why?
|
Colon | 1 | 2018 | 1772 | 0.370 |
Why?
|
Immunocompromised Host | 1 | 2015 | 847 | 0.350 |
Why?
|
Middle Aged | 30 | 2023 | 213383 | 0.340 |
Why?
|
Obesity | 4 | 2021 | 12745 | 0.340 |
Why?
|
Patient Selection | 2 | 2020 | 4215 | 0.330 |
Why?
|
Capsules | 2 | 2019 | 196 | 0.330 |
Why?
|
Indiana | 2 | 2019 | 92 | 0.320 |
Why?
|
Liver Transplantation | 1 | 2019 | 2119 | 0.320 |
Why?
|
Vancomycin | 2 | 2023 | 501 | 0.310 |
Why?
|
Immunosuppressive Agents | 3 | 2023 | 4149 | 0.310 |
Why?
|
Aged, 80 and over | 13 | 2021 | 57776 | 0.310 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2020 | 9959 | 0.290 |
Why?
|
Prospective Studies | 15 | 2022 | 53288 | 0.280 |
Why?
|
Intestinal Mucosa | 2 | 2016 | 3036 | 0.280 |
Why?
|
Patient Participation | 3 | 2019 | 1457 | 0.270 |
Why?
|
Intestines | 2 | 2016 | 1924 | 0.270 |
Why?
|
Secondary Prevention | 3 | 2023 | 1530 | 0.260 |
Why?
|
Male | 32 | 2022 | 350118 | 0.260 |
Why?
|
Female | 34 | 2023 | 380194 | 0.260 |
Why?
|
Wound Healing | 1 | 2016 | 2785 | 0.260 |
Why?
|
Biological Factors | 2 | 2024 | 164 | 0.260 |
Why?
|
Spores, Bacterial | 2 | 2023 | 118 | 0.260 |
Why?
|
Aged | 20 | 2023 | 163280 | 0.250 |
Why?
|
Tramadol | 1 | 2023 | 51 | 0.230 |
Why?
|
Enteropathogenic Escherichia coli | 1 | 2023 | 27 | 0.230 |
Why?
|
DNA, Bacterial | 2 | 2019 | 1465 | 0.220 |
Why?
|
Young Adult | 13 | 2023 | 56430 | 0.220 |
Why?
|
Mesalamine | 1 | 2023 | 136 | 0.210 |
Why?
|
Risk Factors | 11 | 2021 | 72290 | 0.210 |
Why?
|
Length of Stay | 1 | 2015 | 6309 | 0.210 |
Why?
|
Bacteria | 4 | 2022 | 2114 | 0.210 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 215 | 0.200 |
Why?
|
Patient Readmission | 1 | 2015 | 3114 | 0.200 |
Why?
|
Boston | 3 | 2019 | 9313 | 0.190 |
Why?
|
Intestinal Polyps | 1 | 2020 | 100 | 0.190 |
Why?
|
Time Factors | 5 | 2021 | 40075 | 0.180 |
Why?
|
Cohort Studies | 7 | 2023 | 40561 | 0.180 |
Why?
|
Polymerase Chain Reaction | 2 | 2021 | 6171 | 0.180 |
Why?
|
Research Subjects | 1 | 2012 | 239 | 0.180 |
Why?
|
Freezing | 1 | 2020 | 303 | 0.180 |
Why?
|
Adenomatous Polyps | 1 | 2020 | 107 | 0.180 |
Why?
|
Arthralgia | 1 | 2024 | 456 | 0.180 |
Why?
|
Alberta | 1 | 2019 | 64 | 0.170 |
Why?
|
Escherichia coli Infections | 1 | 2023 | 532 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2023 | 2282 | 0.160 |
Why?
|
Amidohydrolases | 1 | 2019 | 169 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 3 | 2022 | 1855 | 0.150 |
Why?
|
Tissue Banks | 1 | 2018 | 184 | 0.150 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2022 | 954 | 0.150 |
Why?
|
Phosphoric Acids | 1 | 2016 | 24 | 0.140 |
Why?
|
Legislation, Drug | 1 | 2018 | 206 | 0.140 |
Why?
|
Dental Cements | 1 | 2016 | 22 | 0.140 |
Why?
|
Phytotherapy | 1 | 2018 | 298 | 0.140 |
Why?
|
Dental Etching | 1 | 2016 | 33 | 0.140 |
Why?
|
End Stage Liver Disease | 1 | 2020 | 314 | 0.140 |
Why?
|
Pilot Projects | 2 | 2019 | 8324 | 0.140 |
Why?
|
Dental Enamel | 1 | 2016 | 64 | 0.140 |
Why?
|
Interleukin-2 | 1 | 2023 | 1904 | 0.140 |
Why?
|
Depression | 1 | 2015 | 7766 | 0.140 |
Why?
|
Probiotics | 1 | 2019 | 351 | 0.130 |
Why?
|
Directive Counseling | 1 | 2017 | 166 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39050 | 0.130 |
Why?
|
Incisor | 1 | 2016 | 179 | 0.130 |
Why?
|
Severity of Illness Index | 5 | 2020 | 15540 | 0.130 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 711 | 0.130 |
Why?
|
Irritable Bowel Syndrome | 1 | 2020 | 445 | 0.130 |
Why?
|
External Fixators | 1 | 2005 | 94 | 0.120 |
Why?
|
Propensity Score | 1 | 2021 | 1781 | 0.120 |
Why?
|
Colectomy | 1 | 2020 | 683 | 0.120 |
Why?
|
Intestinal Diseases | 1 | 2019 | 530 | 0.120 |
Why?
|
Practice Guidelines as Topic | 3 | 2023 | 7279 | 0.120 |
Why?
|
Finger Joint | 1 | 2005 | 108 | 0.120 |
Why?
|
Perception | 1 | 2021 | 1198 | 0.120 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2018 | 2557 | 0.120 |
Why?
|
Genes, Bacterial | 1 | 2017 | 1079 | 0.120 |
Why?
|
Finger Injuries | 1 | 2005 | 139 | 0.110 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12354 | 0.110 |
Why?
|
Risk Assessment | 3 | 2019 | 23338 | 0.110 |
Why?
|
Mucous Membrane | 1 | 2016 | 673 | 0.110 |
Why?
|
Regression Analysis | 2 | 2021 | 6459 | 0.110 |
Why?
|
Drug Administration Schedule | 1 | 2021 | 4933 | 0.110 |
Why?
|
Biological Therapy | 1 | 2014 | 138 | 0.110 |
Why?
|
Attitude to Health | 1 | 2012 | 2052 | 0.110 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15076 | 0.110 |
Why?
|
Drug Utilization | 1 | 2018 | 1183 | 0.100 |
Why?
|
Fracture Fixation | 1 | 2005 | 354 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2020 | 1206 | 0.100 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6489 | 0.090 |
Why?
|
Consensus | 1 | 2019 | 2959 | 0.090 |
Why?
|
United States | 8 | 2021 | 69872 | 0.090 |
Why?
|
Cross Infection | 1 | 2018 | 1416 | 0.080 |
Why?
|
Analgesics, Opioid | 2 | 2023 | 3674 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3278 | 0.080 |
Why?
|
Prognosis | 3 | 2019 | 29063 | 0.080 |
Why?
|
Forecasting | 1 | 2017 | 2951 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 5391 | 0.080 |
Why?
|
C-Reactive Protein | 2 | 2017 | 3778 | 0.080 |
Why?
|
Organ Transplantation | 1 | 2018 | 1139 | 0.080 |
Why?
|
Pain | 1 | 2023 | 4986 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2016 | 21746 | 0.080 |
Why?
|
Antibodies, Monoclonal | 2 | 2021 | 9274 | 0.080 |
Why?
|
Metabolomics | 1 | 2016 | 1484 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2278 | 0.070 |
Why?
|
Hearing Loss, Sensorineural | 1 | 1993 | 770 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2017 | 2266 | 0.070 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12245 | 0.070 |
Why?
|
Biodiversity | 2 | 2018 | 341 | 0.060 |
Why?
|
Risk | 1 | 2017 | 9687 | 0.060 |
Why?
|
Diarrhea | 2 | 2023 | 1348 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8089 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6538 | 0.060 |
Why?
|
Massachusetts | 1 | 2017 | 8663 | 0.060 |
Why?
|
Patient Discharge | 1 | 2017 | 3313 | 0.060 |
Why?
|
Codeine | 1 | 2023 | 49 | 0.060 |
Why?
|
Coronary Artery Bypass | 1 | 1993 | 2289 | 0.060 |
Why?
|
Pandemics | 2 | 2020 | 8388 | 0.060 |
Why?
|
Adolescent | 5 | 2023 | 85781 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6364 | 0.050 |
Why?
|
Fractures, Bone | 1 | 2005 | 1947 | 0.050 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2022 | 13 | 0.050 |
Why?
|
Microviridae | 1 | 2021 | 3 | 0.050 |
Why?
|
Quality of Life | 1 | 2022 | 12804 | 0.050 |
Why?
|
Proteobacteria | 1 | 2021 | 45 | 0.050 |
Why?
|
Hospitalization | 2 | 2020 | 10262 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5137 | 0.050 |
Why?
|
Fatty Acids, Volatile | 1 | 2020 | 102 | 0.050 |
Why?
|
Body Mass Index | 1 | 2017 | 12720 | 0.040 |
Why?
|
Anastomosis, Surgical | 1 | 2023 | 987 | 0.040 |
Why?
|
Glycocholic Acid | 1 | 2019 | 3 | 0.040 |
Why?
|
Acetaminophen | 1 | 2023 | 545 | 0.040 |
Why?
|
Teaching Rounds | 1 | 2023 | 253 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2015 | 4468 | 0.040 |
Why?
|
Bacteriophages | 1 | 2021 | 356 | 0.040 |
Why?
|
Metagenomics | 1 | 2021 | 428 | 0.040 |
Why?
|
Animals | 5 | 2020 | 168757 | 0.040 |
Why?
|
Analgesics | 1 | 2023 | 1040 | 0.040 |
Why?
|
Risk Adjustment | 1 | 2020 | 594 | 0.030 |
Why?
|
Pyrroles | 1 | 2023 | 1146 | 0.030 |
Why?
|
Interleukin-1 | 1 | 2020 | 1263 | 0.030 |
Why?
|
Nose | 1 | 2019 | 509 | 0.030 |
Why?
|
Living Donors | 1 | 2020 | 620 | 0.030 |
Why?
|
Mice | 2 | 2019 | 81183 | 0.030 |
Why?
|
Administration, Oral | 1 | 2023 | 3913 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 25043 | 0.030 |
Why?
|
Fibrosis | 1 | 2022 | 2029 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3282 | 0.030 |
Why?
|
Specimen Handling | 1 | 2019 | 694 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2023 | 1637 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2065 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2021 | 1035 | 0.030 |
Why?
|
Drug Discovery | 1 | 2021 | 1058 | 0.030 |
Why?
|
Infection Control | 1 | 2020 | 966 | 0.030 |
Why?
|
Netherlands | 1 | 2017 | 2170 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2019 | 1157 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 526 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2016 | 783 | 0.030 |
Why?
|
Inflammation | 2 | 2022 | 10638 | 0.030 |
Why?
|
Cholesterol | 1 | 2020 | 2917 | 0.020 |
Why?
|
Postoperative Complications | 1 | 1993 | 15295 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2020 | 2107 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1863 | 0.020 |
Why?
|
Cattle | 1 | 2016 | 3922 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12026 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2020 | 2708 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3638 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9849 | 0.020 |
Why?
|
Range of Motion, Articular | 1 | 2005 | 1578 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3743 | 0.020 |
Why?
|
Joint Instability | 1 | 2005 | 792 | 0.020 |
Why?
|
Insulin Resistance | 1 | 2020 | 3864 | 0.020 |
Why?
|
Equipment Design | 1 | 2005 | 3582 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15226 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2022 | 13989 | 0.020 |
Why?
|
Blood Glucose | 1 | 2020 | 6256 | 0.020 |
Why?
|
Mass Screening | 1 | 2020 | 5255 | 0.010 |
Why?
|
Models, Biological | 1 | 2018 | 9583 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 21827 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 20947 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18029 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10180 | 0.010 |
Why?
|